U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H22FN3O4
Molecular Weight 375.3941
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GATIFLOXACIN ANHYDROUS

SMILES

COC1=C(N2CCNC(C)C2)C(F)=CC3=C1N(C=C(C(O)=O)C3=O)C4CC4

InChI

InChIKey=XUBOMFCQGDBHNK-UHFFFAOYSA-N
InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)

HIDE SMILES / InChI
Gatifloxacin is a recently developed antibacterial agent differing from earlier fluoroquinolones by the presence of a methoxy group at the C-8 position. The presence of the methoxy group has conferred improved antibacterial activity against both Gram-positive and Gram-negative organisms, making gatifloxacin a broad-spectrum antimicrobial agent applicable in many clinical settings. Gatifloxacin is sold under the brand Zymar and is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic Gram-Positive Bacteria: Cornyebacterium propinquum, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis, Streptococcus pneumoniae and Aerobic Gram-Negative Bacteria: Haemophilus influenza. The antibacterial action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. In addition, Gatifloxacin inhibits bacterial topoisomerase IV. This enzyme is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. There is no cross-resistance between gatifloxacin and the aforementioned classes of antibiotics. Cross-resistance has been observed between systemic gatifloxacin and some other fluoroquinolones.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rats. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ZYMAR

Approved Use

ZYMAXID® (gatifloxacin ophthalmic solution) 0.5% solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic Gram-Positive Bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group* Streptococcus oralis * Streptococcus pneumoniae Aerobic Gram-Negative Bacteria: Haemophilus influenzae *Efficacy for this organism was studied in fewer than 10 infections. ZYMAXID® ophthalmic solution is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group* , Streptococcus oralis * , Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections. (1)

Launch Date

2003
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.2 μg/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.6 μg/mL
400 mg 1 times / day steady-state, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.2 μg/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.8 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5.5 μg/mL
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
34.4 μg × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
35.4 μg × h/mL
400 mg 1 times / day steady-state, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
51 μg × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
33 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
35.1 μg × h/mL
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.1 h
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
13.9 h
400 mg 1 times / day steady-state, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.8 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.4 h
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
80%
400 mg 1 times / day steady-state, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
80%
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
80%
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GATIFLOXACIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg/kg 1 times / day steady, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, 6 - 48 months
n = 160
Health Status: unhealthy
Condition: acute otitis media
Age Group: 6 - 48 months
Sex: M
Population Size: 160
Sources:
Disc. AE: Vomiting, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Vomiting (15 patients)
Diarrhea (3 patients)
Dehydration (2 patients)
Maculopapular rash (2 patients)
Sources:
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Co-administed with::
glyburide(10 mg/day)
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Condition: type 2 diabetes mellitus and pneumonia
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hyperglycemia...
AEs leading to
discontinuation/dose reduction:
Hyperglycemia (1 patient)
Sources:
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Co-administed with::
glyburide(5 mg/day)
Sources:
unhealthy, 84 years
n = 1
Health Status: unhealthy
Condition: type 2 diabetes mellitus and nonproductive cough
Age Group: 84 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hyperglycemia...
AEs leading to
discontinuation/dose reduction:
Hyperglycemia (1 patient)
Sources:
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Co-administed with::
metoprolol, diltiazem, subcutaneous heparin, ranitidine, vancomycin, piperacillin/tazobactam, and aspirin
Sources:
unhealthy, 86 years
n = 1
Health Status: unhealthy
Condition: small bowel obstruction and suspected pneumonia
Age Group: 86 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hyperglycemia...
AEs leading to
discontinuation/dose reduction:
Hyperglycemia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Vomiting 15 patients
Disc. AE
10 mg/kg 1 times / day steady, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, 6 - 48 months
n = 160
Health Status: unhealthy
Condition: acute otitis media
Age Group: 6 - 48 months
Sex: M
Population Size: 160
Sources:
Dehydration 2 patients
Disc. AE
10 mg/kg 1 times / day steady, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, 6 - 48 months
n = 160
Health Status: unhealthy
Condition: acute otitis media
Age Group: 6 - 48 months
Sex: M
Population Size: 160
Sources:
Maculopapular rash 2 patients
Disc. AE
10 mg/kg 1 times / day steady, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, 6 - 48 months
n = 160
Health Status: unhealthy
Condition: acute otitis media
Age Group: 6 - 48 months
Sex: M
Population Size: 160
Sources:
Diarrhea 3 patients
Disc. AE
10 mg/kg 1 times / day steady, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, 6 - 48 months
n = 160
Health Status: unhealthy
Condition: acute otitis media
Age Group: 6 - 48 months
Sex: M
Population Size: 160
Sources:
Hyperglycemia 1 patient
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Co-administed with::
glyburide(10 mg/day)
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Condition: type 2 diabetes mellitus and pneumonia
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Hyperglycemia 1 patient
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Co-administed with::
glyburide(5 mg/day)
Sources:
unhealthy, 84 years
n = 1
Health Status: unhealthy
Condition: type 2 diabetes mellitus and nonproductive cough
Age Group: 84 years
Sex: F
Population Size: 1
Sources:
Hyperglycemia 1 patient
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Co-administed with::
metoprolol, diltiazem, subcutaneous heparin, ranitidine, vancomycin, piperacillin/tazobactam, and aspirin
Sources:
unhealthy, 86 years
n = 1
Health Status: unhealthy
Condition: small bowel obstruction and suspected pneumonia
Age Group: 86 years
Sex: M
Population Size: 1
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
1992 Oct
Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
1993 Jun
N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
1996 Nov
Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.
1996 Oct
[In vitro anti-MAC activities of new quinolones in focus (2)].
1996 Sep
[In vitro anti-MAC activities of new quinolones in focus (1)].
1996 Sep
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
1997 Apr
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
1999 Dec
In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
2000 Apr
Antimycobacterial activities of novel levofloxacin analogues.
2000 Aug
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.
2000 Oct
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.
2000 Oct
Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.
2000 Sep
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
2001 Dec
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
2002 Apr
In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum.
2002 Feb
Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex.
2002 Feb
Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis.
2003 Apr
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis.
2003 Aug
Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice.
2003 Feb
Fluoroquinolones as chemotherapeutics against mycobacterial infections.
2004
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.
2004 Apr
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis.
2004 Apr
Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
2004 Jun 7
Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
2004 Mar
Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.
2004 Mar
Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
2004 Nov
Gatifloxacin-induced cholestatic hepatitis--a challenging diagnosis.
2005 Mar
Antimicrosporidial activity of (fluoro)quinolones in vitro and in vivo.
2005 May
Fluoroquinolones: an important class of antibiotics against tuberculosis.
2006
Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.
2006 Apr
Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones.
2006 Dec
Serious adverse drug effects--seeing the trees through the forest.
2006 Mar 30
Outpatient gatifloxacin therapy and dysglycemia in older adults.
2006 Mar 30
Development and validation of an ion-pairing RP-HPLC method for the estimation of gatifloxacin in bulk and formulations.
2007 Apr
[Status epilepticus and gatifloxacin].
2007 Jan
Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.
2008 Mar 1
Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
2008 Mar 15
Synthesis and in-vitro antimycobacterial evaluation of 1-(cyclopropyl/2,4-difluorophenyl/tert-butyl)-1,4-dihydro- 8-methyl-6-nitro-4-oxo-7-(substituted secondary amino)quinoline-3-carboxylic acids.
2009 Feb
Antimycobacterial activities of novel fluoroquinolones.
2009 Jan
Antituberculosis activity of the molecular libraries screening center network library.
2009 Sep
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
2010 Aug
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
2010 Jun
A comparative analysis of chromosomal aberrations in cultured human lymphocytes due to fluoroquinolone drugs at different expression periods.
2010 May
Safety profile of the fluoroquinolones: focus on levofloxacin.
2010 May 1
Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
2011 Apr
Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats.
2013 Feb 1
Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
2013 Feb 15
Patents

Patents

Sample Use Guides

The recommended dosage regimen for the treatment of bacterial conjunctivitis is: Days 1 and 2: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times daily. Days 3 through 7: Instill one drop up to four times daily while awake.
Route of Administration: Other
Gatifloxacin was synergic with the beta-lactams piperacillin, cefepime and meropenem, and with gentamicin against some drug-resistant pathogens. It was investigated in vitro interaction of gatifloxacin in combination with these drugs against clinical isolates of Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Burkholderia cepacia, extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae, vancomycin-resistant Enterococcus faecium (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Synergy was demonstrated with the following combinations at achievable serum concentrations: gatifloxacin/piperacillin for 80% and gatifloxacin/cefepime for 60% of S. maltophilia; gatifloxacin/gentamicin for 60%, and gatifloxacin/cefepime for 50% of ESBL-producing K. pneumoniae, and in all drug combinations for 50-70% of P. aeruginosa. Indifference was noted for the majority of B. cepacia and VRE isolates. Antagonism at therapeutic serum levels was observed with gatifloxacin/piperacillin against a single isolate of B. Cepacia. MIC50 and MIC90 values represent the concentrations at which 50% and 90% of strains, respectively, were inhibited. The gatifloxacin MICs for S. maltophilia ranged from 0.5 to 4 mg/L, the lowest values of the agents tested. Gatifloxacin at 2 mg/L in combination with cefepime at 8 mg/L, and gatifloxacin at 2 mg/L in combination with piperacillin at 64 mg/L, resulted in at least a 2 log10 decrease in viable colonies, and by definition were synergic.
Name Type Language
GATIFLOXACIN ANHYDROUS
Common Name English
GATIFLOXACIN [MI]
Common Name English
(±)-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL)-4-OXO-3-QUINOLINECARBOXYLIC ACID
Systematic Name English
ZYMER
Brand Name English
Gatifloxacin [WHO-DD]
Common Name English
gatifloxacin [INN]
Common Name English
NSC-758701
Code English
Classification Tree Code System Code
WHO-ATC J01MA16
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
WHO-ATC S01AX21
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
NDF-RT N0000007606
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
NDF-RT N0000175937
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
LIVERTOX NBK547840
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
Code System Code Type Description
INN
7423
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
EVMPD
SUB13952MIG
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
EPA CompTox
DTXSID5045704
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
NSC
758701
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
DRUG BANK
DB01044
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
FDA UNII
81485Y3A9A
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
DAILYMED
81485Y3A9A
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
RXCUI
1546025
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C175722
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
PUBCHEM
5379
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
SMS_ID
100000090510
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
MERCK INDEX
m5679
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY Merck Index
CAS
112811-59-3
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY
WIKIPEDIA
Gatifloxacin
Created by admin on Fri Dec 15 15:44:07 GMT 2023 , Edited by admin on Fri Dec 15 15:44:07 GMT 2023
PRIMARY